Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manyi Xu

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Medical Oncology (Northwood, London, England)|June 9, 2023
Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective studyManyi Xu, Yue Hao, Huan Zhou, et al.
Cancer Medicine|June 12, 2023
Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutationsYue Hao, Manyi Xu, Jianan Jin, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 16, 2024
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatmentKe Wang, Manyi Xu, Yanhua Wang, et al.
Journal of Proteome Research|January 30, 2023
Concentration-Dependent Enrichment Identifies Primary Protein Targets of Multitarget Bioactive MoleculesManyi Xu, Xingyu Ma, Zi Ye, et al.
Chemical Communications (Cambridge, England)|October 9, 2024
New electrophiles targeting thiols in a reversible covalent mannerXingyu Ma, Manyi Xu, Fengge Wang, et al.
Medical Oncology (Northwood, London, England)|December 2, 2022
Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709XYue Hao, Manyi Xu, Huan Zhou, et al.
Journal of Thoracic Disease|March 13, 2023
Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinomaJingwen Wei, Jing Xiang, Yue Hao, et al.
Investigational New Drugs|December 1, 2024
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective studyManyi Xu, Yanhua Wang, Ke Wang, et al.
European Journal of Medicinal Chemistry|May 31, 2017
Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activityNa Bao, Jinfeng Ou, Manyi Xu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 16, 2024
Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterationsYanhua Wang, Jingwen Wei, Manyi Xu, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Medical Oncology (Northwood, London, England)|June 9, 2023
Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective studyManyi Xu, Yue Hao, Huan Zhou, et al.
Cancer Medicine|June 12, 2023
Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutationsYue Hao, Manyi Xu, Jianan Jin, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 16, 2024
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatmentKe Wang, Manyi Xu, Yanhua Wang, et al.
Journal of Proteome Research|January 30, 2023
Concentration-Dependent Enrichment Identifies Primary Protein Targets of Multitarget Bioactive MoleculesManyi Xu, Xingyu Ma, Zi Ye, et al.
Chemical Communications (Cambridge, England)|October 9, 2024
New electrophiles targeting thiols in a reversible covalent mannerXingyu Ma, Manyi Xu, Fengge Wang, et al.
Medical Oncology (Northwood, London, England)|December 2, 2022
Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709XYue Hao, Manyi Xu, Huan Zhou, et al.
Journal of Thoracic Disease|March 13, 2023
Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinomaJingwen Wei, Jing Xiang, Yue Hao, et al.
Investigational New Drugs|December 1, 2024
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective studyManyi Xu, Yanhua Wang, Ke Wang, et al.
European Journal of Medicinal Chemistry|May 31, 2017
Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activityNa Bao, Jinfeng Ou, Manyi Xu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 16, 2024
Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterationsYanhua Wang, Jingwen Wei, Manyi Xu, et al.
Pageof 5